Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
T Regulatory Cells for GVHD Suppression in UCB Transplant
NCT02118311Phase 2Withdrawn
- Sponsor
- Masonic Cancer Center
- Start
- Jun 2016
- Primary completion
- Sep 2018
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
A Phase 2 trial of umbilical cord blood regulatory T cells in Acute Graft-Versus-Host Disease (aGvHD), sponsored by Masonic Cancer Center. Planned start Jun 2016; status: withdrawn.
02
Drugs
umbilical cord blood regulatory T cells
03
Conditions
Acute Graft-Versus-Host Disease (aGvHD)
Beyond the preview
Go deeper on NCT02118311.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02118311.